ReNEW and ReGAIN are two global research studies evaluating an investigational therapy in subjects with dry age-related macular degeneration (Dry AMD).
Dry AMD is a leading cause of blindness impacting more than five million people worldwide, which can severely impair visual function, independence, and quality of life. Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to progressive loss of vision.
If you are a patient who is at least 55 years of age with dry AMD in one eye, you may be eligible for the ReNEW or ReGAIN trials evaluating Dry AMD treatment.
Find the participating ReNEW and ReGAIN research sites(s) nearest you.
This site was developed by Stealth BioTherapeutics Inc. to provide information about ReNEW and ReGAIN.
